Independent Study by Fraunhofer Institute in Germany, Using Pluristem Life Systems Inc. 's PLX Cells, Shows Promise in the Treatment of Ischemic Stroke
10/18/2007 12:35:28 PM
NEW YORK--(BUSINESS WIRE)--Pluristem Life Systems, Inc. (OTCBB:PLRS) (DAX:PJT), a bio-therapeutics Company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for a variety of malignant, degenerative and auto-immune indications, announced today that results from Fraunhofer Institute’s ongoing in vivo study, utilizing Pluristem’s proprietary PLacenta eXpanded (PLX) cells in treating ischemic stroke, showed initial promise as a potential therapy to treat stroke victims. PLX cells are mesenchymal stem cells (MSCs) obtained from the placenta and expanded using Pluristem’s proprietary 3D PluriX™ technology.
comments powered by